Tegaserod Availability in the United States
Yes, tegaserod (Zelnorm) is currently available in the United States, but only under highly restricted FDA approval for a specific patient population. 1
Current FDA Approval Status
Tegaserod was reapproved by the FDA with limited indication after being withdrawn from the market in 2007. The drug is now available exclusively for:
- Women under 65 years of age
- With irritable bowel syndrome with constipation (IBS-C)
- Without a history of cardiovascular ischemic events (myocardial infarction, stroke, TIA, or angina) 2, 1
Critical Exclusions - Who Cannot Receive Tegaserod
The following patients are absolutely contraindicated from receiving tegaserod 1:
- Men (safety and efficacy not established)
- Women ≥65 years of age
- Any history of heart attack, stroke, TIA, or angina
- History of ischemic colitis
- Severe kidney problems or end-stage kidney disease
- Moderate or severe liver problems
- History of bowel obstruction or symptomatic gallbladder disease
- Sphincter of Oddi dysfunction
Regulatory History Context
The 2022 AGA Clinical Practice Guidelines provide a conditional recommendation for tegaserod use in IBS-C patients (moderate certainty evidence) 2. This reflects the drug's complex regulatory journey:
- 2002: Initial FDA approval for IBS-C in women
- 2004: Expanded approval for chronic idiopathic constipation in both sexes under 65
- 2007: Market withdrawal due to cardiovascular safety concerns (13 of 11,614 patients [0.11%] vs 1 of 7031 [0.01%] on placebo experienced cardiovascular ischemic events)
- 2019: Limited reapproval after FDA re-examination showed cardiovascular risk was predominantly in patients with pre-existing cardiovascular disease or risk factors 2, 3
Clinical Efficacy in Approved Population
In the FDA-approved population (women <65 without cardiovascular disease), tegaserod demonstrates:
- FDA responder rate: 35.1% vs 23.4% placebo (RR 0.87,95% CI 0.81-0.93)
- Global symptom relief: 52.7% vs 44.8% placebo
- Abdominal pain improvement: 22.4% vs 17.6% placebo
- Bowel movement frequency improvement: 65.6% vs 51.2% placebo 2, 4
Important Safety Monitoring
Cardiovascular risk factors requiring discussion before prescribing 1:
- Current smoking
- Hypertension (even if controlled)
- Hyperlipidemia (even if controlled)
- Diabetes mellitus
- Age ≥55 years
- Obesity
Patients must be counseled to immediately discontinue tegaserod and seek emergency care if they develop symptoms of MI, stroke, TIA, or angina while on therapy 1.
Practical Prescribing Information
- Dosing: 6 mg twice daily, taken at least 30 minutes before meals 1
- Distribution: Alfasigma USA, Inc. (1-855-697-9232)
- Availability: Prescription only, supplied as blister packs (10,30, or 60 tablets) 1
Clinical Context
While tegaserod is available, the AGA guidelines note it carries only a conditional recommendation due to moderate certainty evidence and the restricted indication 2. Other agents like linaclotide received strong recommendations with high certainty evidence for IBS-C 2. Therefore, tegaserod should typically be considered after other first-line therapies in appropriately selected low-cardiovascular-risk women under 65.